Primary myelofibrosis (PMF) is characterized by bone marrow fibrosis, myeloproliferation, extramedullary hematopoiesis, splenomegaly and leukemic progression. Moreover, the bone marrow and spleens of individuals with PMF contain large numbers of atypical megakaryocytes that are postulated to contribute to fibrosis through the release of cytokines, including transforming growth factor (TGF)-b. Although the Janus kinase inhibitor ruxolitinib provides symptomatic relief, it does not reduce the mutant allele burden or substantially reverse fibrosis. Here we show through pharmacologic and genetic studies that aurora kinase A (AURKA) represents a new therapeutic target in PMF. Treatment with MLN8237, a selective AURKA inhibitor, promoted polyploidization and differentiation of megakaryocytes with PMF-associated mutations and had potent antifibrotic and antitumor activity in vivo in mouse models of PMF. Moreover, heterozygous deletion of Aurka was sufficient to ameliorate fibrosis and other PMF features in vivo. Our data suggest that megakaryocytes drive fibrosis in PMF and that targeting them with AURKA inhibitors has the potential to provide therapeutic benefit. npg
Although the median survival for individuals with PMF, a subtype of myeloproliferative neoplasms (MPNs), is 5-7 years, those with intermediate and high-risk disease (as defined by the Dynamic International Prognostic Scoring System Plus) have a median survival of just 16-35 months 1 . PMF can develop into acute leukemia and is associated with pancytopenia, thrombosis and cardiac complications, infection and bleeding 2 . Within the bone marrow of individuals with PMF, there are excessive numbers of megakaryocytes with an abnormal nuclear/cytoplasmic ratio and a reduced polyploid state. Experiments using in vitro cultures of CD34 + hematopoietic stem cells have shown that megakaryocytes that harbor PMF-associated mutations (hereafter referred to as PMF megakaryocytes) expand excessively, are immature and show delayed apoptosis owing to increased expression of the anti-apoptotic factor Bcl-xL 3 . Mutations associated with PMF include those that affect genes involved in signaling by the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) factors (such as JAK2 and MPL, which encodes the surface receptor for the megakaryocyte growth and differentiation factor thrombopoietin (THPO)), endoplasmic reticulum stress (such as CALR, which encodes the Ca 2+ -binding protein calreticulin), epigenetic regulation (such as TET2 and ASXL1) and RNA splicing (such as SRSF2 and SF3B1) [4] [5] [6] [7] [8] . Although ruxolitinib, a JAK inhibitor approved for use in individuals with PMF 9, 10 , provides symptomatic relief and extends survival, it does not reduce the mutant allele burden or alter the natural history of the disease 2, 11, 12 . Moreover, many patients are intolerant to ruxolitinib and discontinue therapy because of its side effects, which include anemia and thrombocytopenia 13 . Thus, additional agents that have fewer side effects, reduce fibrosis and decrease the mutant allele burden are needed.
Several lines of evidence suggest that increased numbers of megakaryocytes in the bone marrow contribute to marrow fibrosis. First, mice that overexpress Thpo, the gene encoding thrombopoietin, develop fibrosis that is associated with increased megakaryocyte numbers 14 . Second, mice with a megakaryocyte-specific deficiency of the transcription factor-encoding gene Gata1 show elevated numbers of immature megakaryocytes in the bone marrow and severe fibrosis 15, 16 . Third, megakaryocytes from individuals with PMF secrete increased levels of the fibrotic cytokine TGF-β, as compared to megakaryocytes from control individuals 3 . However, the extent to which megakaryocytes are required for myelofibrosis and whether targeting the megakaryocyte lineage is sufficient to treat the disease has not been shown.
We recently reported the identification of small molecules that induce megakaryocyte polyploidization, differentiation and subsequent apoptosis 17 . One of these compounds is the AURKA inhibitor MLN8237 (ref. 18) . Because megakaryocytes in PMF show impaired differentiation, we hypothesized that AURKA inhibition would induce megakaryocyte maturation similar to the effect of MLN8237 on malignant undifferentiated megakaryocytes in acute megakaryocytic leukemia 17 , reduce the burden of immature megakaryocytes and ameliorate the characteristics of PMF, including bone marrow fibrosis. Here we find that AURKA activity is strongly elevated in cells that harbor activating mutations in JAK2, MPL or CALR. Moreover, MLN8237 treatment induces the differentiation and polyploidization of PMF megakaryocytes and reduces disease burden in two mouse models of PMF, Jak2 V617F and MPL W515L mice. We also demonstrate that AURKA is a tractable therapeutic target in PMF, as loss of a single Aurka allele is sufficient to prevent PMF phenotypes in vivo.
RESULTS

Inhibition of AURKA induces differentiation of JAK2-or MPL-mutated cells
On the basis of our previous studies showing that the AURKA inhibitor MLN8237 promotes the maturation of malignant megakaryocytes, as well as our hypothesis that atypical megakaryocytes contribute directly to myelofibrosis, we investigated the activity of AURKA inhibitors in PMF. First, we assayed the effect of MLN8237 on the human erythroleukemia (HEL) cell line, which is positive for JAK2 V617F and is responsive to JAK2 inhibition 19 . MLN8237 treatment decreased the levels of the kinase-active, T288-phosphorylated form of AURKA 18 (p-AURKA) but not those of phosphorylated STAT3 (p-STAT3) or STAT5 (p-STAT5), whereas ruxolitinib treatment decreased the levels of p-STAT3 and p-STAT5 but not p-AURKA (Supplementary Fig. 1a) . MLN8237 potently inhibited cell growth, with an IC 50 (the half-maximal inhibitory concentration) of 26.5 nM, whereas the IC 50 for ruxolitinib was 343 nM (Supplementary Fig. 1b) . MLN8237 treatment induced polyploidization and upregulation of the megakaryocyte cell surface markers CD41 and CD42 ( Supplementary Fig. 1c-e) . By contrast, ruxolitinib treatment did not have these effects on cell differentiation. Similarly, treatment with MLN8237 but not ruxolitinib displayed growth inhibition and megakaryocyte differentiation activity on the G1ME/MPLW515L cell line (Supplementary Fig. 2) , which lacks the erythromegakaryocytic transcription factor GATA1 and expresses the W515L mutant, activated form of MPL (MPL W515L ). This cell line, derived from GATA1-deficient embryonic stem cells, can differentiate into megakaryocytes upon restoration of GATA1 (ref. 20) . G1ME cells are relevant to PMF because patients express reduced levels of GATA1 (ref. 21) , and mice that lack GATA1 in megakaryocytes develop profound bone marrow fibrosis 16 . Finally, similar effects were observed in SET-2 cells (Supplementary Fig. 3a-e) , a human megakaryocytic cell line derived from a patient expressing JAK2 V617F (ref. 22) .
Next, we extracted protein from bone marrow cells of Jak2 V617F knock-in mice 23 or from mice transplanted with mouse bone marrow cells overexpressing MPL W515L or either of two different CALR-mutated genes (CALR type 1 and CALR type 2) 7,8 ; we then assayed the phosphorylation status of AURKA, STAT3 and STAT5. As expected, expression of Jak2 V617F , MPL W515L or mutated CALR led to increased levels of phosphorylated STAT5 relative to controls ( Fig. 1a and Supplementary Fig. 4) . Moreover, expression of these mutant proteins led to a striking upregulation of both phosphorylated and total AURKA levels (Fig. 1a, Supplementary Fig. 4 and data not shown). MLN8237 treatment of primary mouse bone marrow cells expressing MPL W515L or Jak2 V617F for 6 h led to a decrease in the levels of phosphorylated AURKA without affecting the levels of p-STAT3 or p-STAT5 (Fig. 1b,c) . Of note, although treatment of these cells with increasing doses of ruxolitinib led to a decrease in p-STAT3 and p-STAT5 levels, p-AURKA levels were reduced only at 24 h after treatment and only at concentrations of ruxolitinib above 1 µM (Supplementary Fig. 5 ). Together, these results show that total and phosphorylated AURKA levels are upregulated by expression of Jak2 V617F , MPL W515L or the CALR mutants, and that MLN8237 and ruxolitinib treatments differentially affect cell signaling. To confirm that p-AURKA levels are indeed elevated in megakaryocytes expressing MPL W515L , we cultured MPL W515L -expressing bone marrow cells with THPO. As we previously reported 24 , the expression of AURKA declines with megakaryocyte maturation, such that very little protein is detected in control cells after 3 d of culture (Supplementary Fig. 6 ). By contrast, megakaryocytes that express MPL W515L displayed persistent p-AURKA expression throughout 7 d of culture.
We next assessed the effect of AURKA inhibition on the growth of MPL W515L -expressing bone marrow cells. Treatment with MLN8237 significantly increased the expression of CD41 and CD42, the degree of polyploidization and the annexin V staining of megakaryocytes, as compared to vehicle-treated cells (Fig. 1d-g ). These results are consistent with our previous observations that AURKA inhibition promotes megakaryocyte differentiation and acts to suppress proliferation of the megakaryocytic lineage 17 . Lastly, we transduced mouse bone marrow cells with retroviruses that express wild-type MPL (MPL WT ) or MPL W515L and cultured the cells in methylcellulose to derive hematopoietic colonies in the presence of increasing doses of MLN8237. MLN8237 treatment preferentially inhibited the colony-forming unit activity (both colony-forming unit-megakaryocyte (CFU-MK) and colony-forming unit-myeloid (CFU-myeloid), which are measures of progenitor cell numbers and activity) of MPL W515L -expressing cells relative to that of MPL WT -expressing cells, even at doses as high as 1 µM (Fig. 1h,i) . This selective effect is probably because of a greater dependence on AURKA activity of cells with activated JAK-STAT signaling.
Previous studies have reported that AURKA expression is elevated downstream of JAK2 V617F and that this effect is mediated by increased c-MYC protein levels [25] [26] [27] . Consistent with this model, we observed increased c-MYC protein levels in bone marrow cells expressing either JAK2 V617F or MPL W515L (Fig. 1a) . To investigate the link between activated JAK-STAT signaling, c-MYC and AURKA, we studied SET-2 cells. c-MYC protein was readily detected in SET-2 cell extracts and its expression was significantly reduced by ruxolitinib at 48 h after treatment ( Supplementary Fig. 3f,g ). This reduction coincided with a decrease in levels of both total and phosphorylated AURKA. By contrast, MLN8237 treatment did not affect c-MYC levels, indicating that the inhibitor acts downstream of the JAK-STAT-MYC axis. To confirm that c-MYC is required for elevated AURKA expression, we knocked down MYC, the gene encoding c-MYC, with either of two short hairpin RNAs (shRNAs). As predicted, MYC knockdown reduced levels of both total and phosphorylated AURKA (Supplementary Fig. 7a ). This reduction was associated with increased expression of CD41 and CD42 and with increased apoptosis (Supplementary Fig. 7b-e) . Of note, the increase in phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) and protein kinase B (AKT) signaling that was observed in JAK2-and MPL-mutated cells (Fig. 1a) is not responsible for the increase in p-AURKA, as treatment of SET-2 cells with the AKT inhibitor MK-2206 did not change p-AURKA levels ( Supplementary Fig. 8 ).
We next investigated whether AURKA is upregulated in patients with PMF, essential thrombocythemia (ET) or polycythemia vera (PV) ( Supplementary Tables 1 and 2 ). Western blot analysis revealed that p-AURKA and AURKA levels are elevated both in CD34 + cells from the peripheral blood of patients with PMF, as compared to CD34 + cells from the cord blood of control individuals, and in peripheral blood mononuclear cells of individuals with ET or PV, as compared to peripheral blood mononuclear cells from healthy individuals ( Fig. 2a and Supplementary Figs. 9 and 10). We also observed elevated expression of c-MYC in mononuclear cells from individuals with PMF, ET and PV, in line with our data from studies of mouse cells and the SET-2 cell line. Similarly to those studies, treatment of primary CD34 + cells from individuals with PMF using MLN8237 led to suppression of p-AURKA levels but not of JAK-STAT signaling (Fig. 2b,c) . Furthermore, whereas ruxolitinib treatment rapidly reduced p-STAT5 levels, it did not affect p-AURKA levels until prolonged incubation. Together, these results support the model that enhanced JAK-STAT signaling indirectly leads to an increase in p-AURKA levels. Lastly, we investigated the effects on MLN8237 treatment on CD34 + cells collected from the peripheral blood of patients with PMF (patients 5-14, Supplementary Table 1) . Treatment with MLN8237 significantly induced the upregulation of CD41 and CD42 levels (Fig. 2d,e) and the polyploidization of CD41 + cells, without affecting the DNA content of CD41 − cells (Fig. 2f) . Moreover, consistent with the concept that AURKA inhibition leads to suppression of the megakaryocyte lineage, MLN8237 treatment also inhibited cell growth (Fig. 2g) .
AURKA inhibitors provide therapeutic benefit in MPN animal models Before testing MLN8237 in mouse models of MPN, we treated healthy BALB/c mice with MLN8237 (15 mg per kg of body weight (mg/kg)) twice daily for 3 weeks. Our previous pharmacokinetic studies 17 showed that a single dose of 15 mg/kg in mice exceeds the IC 50 for growth inhibition in MPL W515L -expressing primary bone marrow cells for >12 h. MLN8237 treatment of BALB/c mice was well tolerated, with no reduction in body weight or peripheral blood cell counts, and no effect on bone marrow composition ( Supplementary Fig. 11 ). Histological analysis of the bone marrow, spleen and liver confirmed that MLN8237 treatment at this dose did not cause myelosuppression or other detrimental effects (Supplementary Fig. 11 ). Transplantation of GFP + bone marrow cells expressing MPL W515L leads to an aggressive form of MPN in recipient animals that is characterized by marked leukocytosis, thrombocytosis, hepatomegaly and splenomegaly and the presence of abnormal megakaryocytes and bone marrow fibrosis 28, 29 . Three weeks after transplantation of the MPL W515L -expressing bone marrow to irradiated BALB/c recipient mice, we verified that all of the animals had >50% GFP + cells in the peripheral blood (data not shown). At this time point, the animals displayed an elevated white cell count (Fig. 3a) , indicative of disease. After randomizing the mice, we treated them twice daily for 3 weeks with 15 mg/kg MLN8237, 60 mg/kg of the AURKA inhibitor dimethylfasudil (diMF) 17 or vehicle. As expected, vehicle-treated mice developed an aggressive PMF syndrome that worsened with time 28, 29 (Fig. 3) . By contrast, treatment with either of the AURKA inhibitors normalized white cell and platelet counts, and also reduced the hematocrit and hemoglobin concentrations (Fig. 3a,b and Supplementary Fig. 12a) ; hemoglobin concentrations are only modestly elevated in this model. Moreover, MLN8237 or diMF treatment reduced spleen and liver weights without affecting body weight ( Fig. 3c and data not shown). Treatment with either drug also reduced the size of the GFP + tumor cell population, as assessed by decreases in both the percentage of GFP + cells and in the median GFP fluorescence intensity (Fig. 3d) . Consistent with the notion that MLN8237 and diMF act as suppressors of the megakaryocyte lineage, we observed dramatic reductions in the sizes of the CD41 and CD42 populations in the spleen as well as an increased degree of megakaryocyte polyploidization (Fig. 3e-g ). MLN8237 and diMF treatments had effects on bone marrow megakaryocytes similar to those observed in the spleen (Supplementary Fig. 12b,c) . Treatment with either drug also reduced the splenic Gr1 + Mac1 + myeloid cell population and the LSK stem cell and myeloid progenitor populations in the bone marrow (Supplementary Fig. 12d ,e and data not shown). Notably, consistent with a previous report that PMF megakaryocytes secrete excessive amounts of TGF-β (ref. 3 ), we observed a significant reduction in TGF-β levels in the plasma of animals after MLN8237 or diMF treatment (Fig. 3h) . Bone marrow histology revealed a robust drop in megakaryocyte mass, accompanied by a striking decline in fibrosis in animals that had been treated with either MLN8237 or diMF (Fig. 3i,j) . We also observed decreased tumor burden in the peripheral blood, spleen, lung and liver (Supplementary Fig. 12f-i) , as well as decreased fibrosis in the spleen (Supplementary Fig. 12j) . Finally, we repeated this study in mice with a more fulminant disease by waiting 30 d after transplantation before treating the mice with drugs. In this setting, MLN8237 treatment rapidly normalized peripheral blood counts and decreased splenomegaly, hepatomegaly and megakaryocyte burden (Supplementary Fig. 13a-e) . This was accompanied by normalization of peripheral blood cytomorphology and of bone marrow, spleen, lung and liver histology, along with variable reduction in bone marrow fibrosis (Supplementary Fig. 13f-j and data not shown).
We next studied the activity of MLN8237 treatment in Jak2 V617F knock-in mice 23 . In this model, recipient mice are transplanted with bone marrow cells from mice with a loxP-flanked ('floxed') Jak2 V617F allele that allows for Vav-Cre-mediated expression of JAK2 V617F ; these animals develop polycythemia, mild leukocytosis, perturbed megakaryopoiesis, splenomegaly, hepatomegaly and myelofibrosis. Four weeks after bone marrow transplantation, we observed polycythemia, leukocytosis and thrombocytosis in the recipient mice. We then treated the animals with 15 mg/kg MLN8237 by oral gavage twice daily for 7 weeks. MLN8237 treatment significantly reduced white blood counts, hematocrit, platelet counts and spleen weight, without affecting body weight (Fig. 4a,b and data not shown). MLN8237 treatment both reduced the number of erythroid cells and megakaryocytes and induced megakaryocyte polyploidy within the bone marrow and spleen (Fig. 4c-g ). Moreover, MLN8237 treatment normalized bone marrow megakaryopoiesis and splenic architecture (Fig. 4h,i) and strikingly attenuated fibrosis in the bone marrow (Fig. 4j) .
AURKA is required for myelofibrosis
Complete loss of Aurka results in early embryonic lethality in mice as a consequence of impaired centrosome separation and defects in bipolar spindle formation, whereas mice with a heterozygous deficiency are viable, fertile and show no hematopoietic defects 24, 30 . To determine the requirement for AURKA expression in the development of myelofibrosis, we crossed mice heterozygous for a floxed Aurka allele with mice expressing Mx1-Cre, which allows for inducible activation of Cre in hematopoietic cells, generating Aurka fl/+ and Aurka fl/+ Mx1-Cre mice. Next, we transduced bone marrow cells from these mice with a retrovirus expressing MPL W515L and transplanted the cells into lethally irradiated WT recipients. We observed equivalent levels of engraftment of Aurka fl/+ and Aurka fl/+ Mx1-Cre cells at 3 weeks after transplantation, as assessed by the levels of GFP + cells (Fig. 5a) . At this time point, we injected Aurka fl/+ and Aurka fl/+ Mx1-Cre mice with polyinosinic-polycytidylic acid (pIpC) to activate the Mx1 promoter and cause expression of Cre recombinase, which resulted in complete excision of the floxed Aurka allele in the cells of the peripheral blood, bone marrow and spleen in mice expressing Mx1-Cre (Fig. 5b) . After the pIpC injection, we observed progression of leukocytosis and thrombocytosis in the control group (i.e., the Aurka fl/+ mice), but not in the group that was deleted for the floxed Aurka allele (i.e., the Aurka fl/+ Mx1-Cre mice) (Fig. 5c,d) .
In contrast to expansion of the GFP + tumor population in the control group, tumor cells with heterozygous Aurka excision failed to expand (Fig. 5a) . Heterozygous loss of Aurka also led to significant reductions in spleen and liver weights, as well as decreased GFP expression in the spleen (Fig. 5e,f and Supplementary Fig. 14a ). In addition, heterozygous loss of Aurka led to decreased percentages of splenic CD41 + and Gr1 + Mac1 + cells but to an increase in the degree of megakaryocyte polyploidization (Fig. 5g,h and Supplementary Fig. 14b ). Finally, heterozygous Aurka deletion decreased tumor burden in the peripheral blood, bone marrow, spleen, lung and liver, and also decreased the degree of bone marrow fibrosis (Fig. 5i,j and Supplementary  Fig. 14c-f) . As expected from our previously published data that mice with complete loss of Aurka develop rapid bone marrow failure 24 , loss of both alleles of Aurka also led to resolution of disease, nearly eliminating the GFP + tumor cell population (Supplementary Fig. 15) . Together, these results show that the full gene dosage of Aurka is required for the initiation and/or progression of MPN in the MPL W515L model, confirming that AURKA is a valid therapeutic target.
MLN8237 synergizes with ruxolitinib in vitro and in vivo
To determine whether AURKA inhibition can increase the effectiveness of ruxolitinib treatment, we analyzed the effects of combination therapy. Because MLN8237 targets the AURKA pathway and ruxolitinib has a primary effect on the JAK-STAT pathway, we predicted that treatment with these two compounds together would have synergistic effects. We determined the IC 50 values of MLN8237 and ruxolitinib on CFU-myeloid formation by bone marrow cells of MPL W515L bone marrow-recipient mice. Individually, MLN8237 and ruxolitinib treatments had similar effects, with IC 50 values of 19.4 nM and 22.7 nM, respectively (Fig. 6a) ; however, treatment with combinations of MLN8237 and ruxolitinib inhibited colony formation to a much greater degree than did treatment with either single agent and showed synergy at multiple doses (Supplementary Table 3) . Next, we evaluated the activity of combination therapy in vivo. Three weeks after engraftment of MPL W515L -expressing bone marrow cells in WT recipient mice, we treated animals with submaximal doses of MLN8237 and ruxolitinib, either as single agents or in combination. Whereas treatment with either single agent at these doses did not alter disease progression, treatment with the combination of the drugs led to marked reductions in both white blood cell counts and platelet counts (Fig. 6b,c) , and to significant decreases in megakaryocyte burden within the bone marrow and spleen (Fig. 6d,e) . The efficacy of this combination was further confirmed by major reductions in tumor burden in the peripheral blood, bone marrow, spleen, lung and liver (Fig. 6f-h and data not shown). Finally, this combination effectively eliminated bone marrow fibrosis (Fig. 6i) . Together, these results demonstrate that MLN8237 synergizes with ruxolitinib and suggest that combined therapy will show superior activity in patients, as compared to treatment with ruxolitinib alone.
DISCUSSION
In 1984, Castro-Malaspina proposed that ineffective megakaryopoiesis and accumulation of intracytoplasmic components lead to an increase in the levels of a megakaryocyte growth factor (later shown to be platelet-derived growth factor (PDGF)) and a decrease in the levels of platelet factor (PF) 4 within the bone marrow 31 . This combination of elevated PDGF, increased collagen production, reduced PF4 and decreased collagen degradation would then lead to a net increase in collagen and fibrosis. Subsequent studies have documented elevated levels of PDGF, TGF-β and basic fibroblast growth factor (bFGF) in megakaryocytes and platelets of patients with PMF 3,32,33 . More recently, bone morphogenetic proteins (BMPs) and the cytokine oncostatin M have been implicated in myelofibrosis 34, 35 . Of these factors, TGF-β produced by megakaryocytes probably has a critical role, as this cytokine is required for the fibrosis that results from increased THPO expression 36 . Whether immature megakaryocytes also drive the other phenotypes in PMF has been less clear. Recipients of Thpo-expressing bone marrow progenitors develop a lethal myeloproliferative disorder with fibrosis and other PMF phenotypes, but in this study, expression of the Thpo transgene was not restricted to megakaryocytes 14 . Moreover, mice with decreased Gata1 expression (Gata1 low mice), which have excessive numbers of immature megakaryocytes in the bone marrow and spleen, develop fibrosis with secondary erythroid defects, but not leukocytosis 16 . These observations suggest that defects in multiple hematopoietic lineages are necessary for PMF pathogenesis. Of note, two elegant recent studies have shown that megakaryocytes influence hematopoietic stem cell (HSC) quiescence 37, 38 , suggesting that malignant megakaryocytes may have a direct adverse effect on the HSC population. These observations also lend credence to the concept that aberrant megakaryocytes drive the entire spectrum of PMF phenotypes. This model does not preclude contributions to fibrosis from other cell types, such as osteoblastic lineage cells (OBCs), which can be remodeled into inflammatory myelofibrotic cells by exposure to bone marrow cells that express the oncogenic BCR-ABL fusion protein 39 . Although this study 39 implicated Mac1 + myeloid cells in the conversion of OBCs, the role of megakaryocytes in this process was not examined.
AURKA is highly expressed in tumor cells and has been investigated as a therapeutic target in cancer. Indeed, we found that the levels of total and phosphorylated AURKA are greatly elevated in cells that express mutated CALR, MPL W515L or JAK2 V617F . Although we cannot formally exclude the possibility that, at least in part, AURKA levels are higher in megakaryocytes from individuals with PMF than in those from normal individuals because PMF megakaryocytes are less mature, the observation that AURKA levels are also elevated in peripheral blood mononuclear cells and purified CD34 + cells from patients with PMF indicates that high levels of AURKA are a common feature of hematopoietic cells in individuals with PMF. Mechanistically, we provide evidence that this phenomenon is mediated by increased expression of c-MYC, which has been shown to be a downstream consequence of activated JAK2 (refs. 25-27) . The increase in p-AURKA levels is probably the result of autophosphorylation 40 . Finally, we discovered that MPN pathogenesis is highly sensitive to AURKA levels, as loss of a single Aurka allele led to profound decrease in tumor burden in vivo without affecting engraftment or inducing myelosuppression. The lack of myelosuppression observed in these mice, combined with the observation that effective doses of MLN8237 are well tolerated and also do not cause myelosuppression, suggests that a therapeutic window exists for which AURKA inhibition will be effective in treating individuals with PMF, without disrupting normal hematopoiesis.
METHODS
Methods and any associated references are available in the online version of the paper. 
